CD274 and non-small cell lung carcinoma: There have been few extensive studies on TIL therapy for NSCLC; despite the potential responsiveness of this malignancy to PD-1/PD-L1 inhibitors and its high mutational burden, TIL therapy may be an appropriate therapeutic option.